

## 2026 AIPNA Companion Meeting @USCAP, San Antonio

Sunday March 22<sup>nd</sup>, 2-4 pm, Room 303B

### **Biomarker Testing in Surgical Pathology for Targeted Cancer Therapies**

#### ***Presentations***

Biomarker testing for targeted therapies of cancers of the genito-urinary tract

Deepika Sirohi

Associate Professor of Pathology, University of California, San Francisco.

Biomarker testing for targeted therapies of cancers of the gastrointestinal tract

Arvind Rishi, Northwell

Associate Professor, Zucker School of Medicine at Hofstra University

Biomarker testing for targeted therapies of cancers of the gastrointestinal tract

Aliya N. Husain

Professor of Pathology, University of Chicago

#### ***Moderators***

Romil Saxena

Professor of Pathology, Emory University

Megha Joshi

Associate Pathologist, Beth Israel Lahey Health

#### **Course Description**

As targeted therapies reach their *carpe diem* moment in medicine, surgical pathology is increasingly called upon to guide the hand that pens the prescription. Requests for biomarker testing are therefore an everyday reality of contemporary surgical pathology practice. However, keeping up with emerging and evolving data can be an overwhelming task. Further anxiety is sometimes introduced by lack of consensus guidelines and requests for non-traditional testing.

This course is designed to disperse some of the fog by summarizing current standard-of-care guidelines in biomarker testing for malignancies of the lung, genito-urinary tract, and gastrointestinal tract. Select “hot” biomarkers emerging on the horizon will also be discussed.

#### **Learning Objectives:**

At the conclusion of this course, participants will be able to

1. Identify key biomarkers relevant to cancers of the lung, gastrointestinal tract and genito-urinary tract.
2. Summarize appropriate testing algorithms and guidelines for biomarker testing in cancers of the lung, gastrointestinal tract and genito-urinary tract.

3. Utilize biopsies appropriately for immunohistochemical, biomarker and molecular testing.
4. Summarize the clinical utility of and pathologists' role in testing and informing management decisions in targeted cancer therapies.